Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-04-13
2010-11-09
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S056000, C514S834000, C514S023000, C514S025000
Reexamination Certificate
active
07829549
ABSTRACT:
Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
REFERENCES:
patent: 2003/0203845 (2003-10-01), Knudsen et al.
patent: 0251134A2 (1988-01-01), None
patent: 2003 171262 A (2003-06-01), None
patent: WO 99/18961 A1 (1999-04-01), None
patent: WO 2004/029095 (2004-04-01), None
Kliem, V., Ringe, B., Barthels, M., Frei, U., Neumann, K.H. (1994) Successful renal transplantation in severe von Willebrand's disease. Nephrology Dialysis Transplantation, vol. 9, p. 837-838.
Bates, et al., “The New Heparins,”Coron. Artery Dis. 9(2-3):65-74 (1998).
Bishop, et al., “Recombinant Biologics For Treatment Of Bleeding Disorders,”Nat. Rev. Drug Discov. 3(8):684-94 (2004).
Bourin, et al., “Glycosaminoglycans And The Regulation Of Blood Coagulation,”Biochem J. 289(Pt 2):313-30 (1993).
Broze, “The Role Of Tissue Factor Pathway Inhibitor In A Revised Coagulation Cascade,”Semin. Haematol. 29(3):159-69 (1992).
Broze, “The Rediscovery and Isolation Of TFPI,”J. Thromb. Haemost. 1(8):1671-5 (2003).
Brummel, et al., “Factor Viia Replacement Therapy in Factor VII Deficiency,”J. Thromb. Haemost. 2(10):1735-44 (2004).
Carcao, et al., “Prophylactic Factor Replacement in Hemophilia,”Blood Rev. 18(2):101-13 (2004).
Church, et al., “Antithrombin Activity Of Fucoidan. The Interaction Of Fucoidan With Heparin Cofactor II, Antithrombin III, And Thrombin,”J. Biol. Chem. 264(6):3618-23 (1989).
Colliec, et al., “Anticoagulant Prperties of a Fucoidan Fraction,”Thromb Res64:143-154 (1991).
Davie, et al., “The Coagulation Cascade: Initiation, Maintenance, And Regulation,”Biochemistry30(43):10363-70 (1991).
Erhardtsen, et al., “Blocking Of Tissue Factor Pathway Inhibitor (TFPI) Shortens The Bleeding Time In Rabbits With Antibody Induced Haemophilia A,”Blood Coagul. Fibrinolysis6(5):388-94 (1995).
Fryer, et al., “Selective O-Desulfation Produces Nonanticoagulant Heparin That Retains Pharmacological Activity In The Lung,”J Pharmacol Exp Ther. 282(1):208-19 (1997).
Giedrojć, et al., “Comparative Study On The In Vitro And In Vivo Activities Of Heparinoids Derivative Investigated On The Animal Model,”J. Cardiovasc. Pharmacol. 34(3):340-5 (1999).
Granert, et al., “Effects Of Polysaccharide Fucoidin On Cerebrospinal Fluid Interleukin-1 And Tumor Necrosis Factor Alpha In Pneumococcal Meningitis In The Rabbit,”Infect. Immun. 67(5):2071-4 (1999).
Hirsh, et al., “New Anticoagulants,”Blood 105(2):453-63 (2005).
Johnson, et al., “Novel Anticoagulants Based On Inhibition Of The Factor Viia/Tissue Factor Pathway,”Coron. Artery Dis. 9(2-3):83-7 (1998).
Kleesiek, et al., “The 536C—>T Transition In The Human Tissue Factor Pathway Inhibitor (TFPI) Gene Is Statistically Associated With A Higher Risk For Venous Thrombosis,”Thromb. Haemost. 82(1):1-5 (1999).
Lee, “Von Willebrand Disease, Hemophilia A And B, And Other Factor Deficiencies,”Int. Anesthesiol. Clin. 42(3):59-76 (2004).
Liu, et al., “Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP),”Thrombosis and Haemostasis95:68-76 (2006).
Luyt, et al., “Low-Molecular-Weight Fucoidan Promotes Therapeutic Revascularization In A Rat Model Of Critical Hindlimb Ischemia,”J. Pharmacol. Exp. Ther. 305(1):24-30 (2003).
MacGregor, et al., “Metabolism Of Sodium Pentosan Polysulphate In Man Measured By A New Competitive Binding Assay For Sulphated Polysaccharides—Comparison With Effects Upon Anticoagulant Activity, Lipolysis And Platelet Alpha-Granule Proteins,”Thromb. Haemost. 53(3):411-4 (1985).
Mann, “Thrombin: Can't Live Without It; Probably Die From It,”Chest 124(3 Suppl):IS-3S (2003).
Mann, “Thrombin Formation,”Chest 124(3 Suppl):4S-10S (2003).
McAuliffe, et al.Chem.Indus. Magazine 5:170-4 (1997).
McCaffrey et al.Biochem. Biophys. Res. Commun. 184(2):773-81 (1992).
Millet, et al. “Antithrombotic And Anticoagulant Activities Of A Low Molecular Weight Fucoidan By The Subcutaneous Route,”Thromb. Haemost. 81:391-5 (1999).
Nordfang, et al. “Inhibition Of Extrinsic Pathway Inhibitor Shortens The Coagulation Time Of Normal Plasma And Of Hemophilia Plasma,”Thromb. Haemost. 66(4):464-67 (1991).
Novotny, et al. “Purification And Properties Of Heparin-Releasable Lipoprotein-Associated Coagulation Inhibitor,”Blood 78(2):394-400 (1991).
Orgueria, et al. “Modular Synthesis Of Heparin Oligosaccharides,”Chem. Eur. J. 9(1):140-69 (2003).
Rapaport, et al., “The Tissue Factor Pathway: How It Has Become A ‘Prima Ballerina’,”Thromb. Haemost. 74(1):7-17 (1995).
Roberts, et al., “Current Concepts Of Hemostasis: Implications For Therapy,”Anesthesiology 100(3):722-30 (2004).
Sinaÿ, “Sugars Slide Into Heparin Activity,”Nature398(6726):377-8 (1999).
Toida et al.Trends in Glyocscience and Glycotechnology15(81):29-46 (2003).
Vicente, et al., “Unbalanced Effects Of 1-23 Dermation Sulfates With Different Sulfation Patterns On Coagulation, Thrombosis And Bleeding,”Thromb Haenos86(5):1215-1220 (2001).
Wang, et al., “N-Desulfated Non-Anticoagulant Heparin Inhibits Leukocyte Adhesion And Transmigration In Vitro And Attenuates Acute Peritonitis And Ischemia And Reperfusion Injury In Vivo,”Inflamm. Res. 51(9):435-43 (2002).
Welsch, et al., “Effect Of Lipoprotein-Associated Coagulation Inhibitor (LACI) On Thromboplastin-Induced Coagulation Of Normal And Hemophiliac Plasmas,”Thromb. Res. 64(2):213-22 (1991).
Westrick, et al., “Deficiency Of Tissue Factor Pathway Inhibitor Promotes Atherosclerosis And Thrombosis In Mice,”Circulation103(25):3044-6 (2001).
Williams, et al., “Comparative Effects Of Heparin And The Sulfatoid GM1474 On Coagulation Parameters In Plasma And Blood From Various Species,”Gen. Pharmacol. 30(3):337-41 (1998).
Veer Van' T C et al., “Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-11”, Journal of Biological Chemistry, American Society of Biolochemical Biologists, Birmingham, US, 272(7):4367-4377 (1997).
Baxter Healthcare S. A.
Baxter International Inc.
Bozicevic Field & Francis LLP
Field Bret E.
Goon Scarlett
LandOfFree
Methods for treating bleeding disorders using sulfated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating bleeding disorders using sulfated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating bleeding disorders using sulfated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243910